Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sara Marsal

Showing results (51-60 of 94) with videos related to

Pageof 10
Sort By:
Plos One|April 8, 2015
Variation at FCGR2A and functionally related genes is associated with the response to anti-TNF therapy in rheumatoid arthritisGabriela Avila-Pedretti, Jesús Tornero, Antonio Fernández-Nebro, et al.
International Journal of Molecular Sciences|September 27, 2025
Differential Expression of Galectin-1 and Galectin-9 in Immune-Mediated Inflammatory DiseasesCristina Valero-Martínez, Marisa Pardines-Ortiz, Nuria Montes, et al.
Frontiers in Immunology|July 18, 2019
A Combined Transcriptomic and Genomic Analysis Identifies a Gene Signature Associated With the Response to Anti-TNF Therapy in Rheumatoid ArthritisAdrià Aterido, Juan D Cañete, Jesús Tornero, et al.
Medicine|June 29, 2017
Cardiovascular disease in immune-mediated inflammatory diseases: A cross-sectional analysis of 6 cohortsBenjamín Fernández-Gutiérrez, Pedro P Perrotti, Javier P Gisbert, et al.
Annals of the Rheumatic Diseases|June 27, 2009
Loss of imprinting of IGF2 characterises high IGF2 mRNA-expressing type of fibroblast-like synoviocytes in rheumatoid arthritisAlejandro Martin-Trujillo, Johanna G I van Rietschoten, Trieneke C G Timmer, et al.
Pharmacogenomics|May 9, 2013
GWAS replication study confirms the association of PDE3A-SLCO1C1 with anti-TNF therapy response in rheumatoid arthritisIsabel Acosta-Colman, Núria Palau, Jesús Tornero, et al.
BMC Medicine|September 10, 2016
Urine metabolome profiling of immune-mediated inflammatory diseasesArnald Alonso, Antonio Julià, Maria Vinaixa, et al.
Reumatologia Clinica|June 9, 2015
2014 update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological therapies in rheumatoid arthritisRaimon Sanmartí, Susana García-Rodríguez, José María Álvaro-Gracia, et al.
Seminars in Arthritis and Rheumatism|May 20, 2020
Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugsXabier Michelena, Helena Borrell, Mireia López-Corbeto, et al.
BMC Musculoskeletal Disorders|April 22, 2021
Interactions between rheumatoid arthritis antibodies are associated with the response to anti-tumor necrosis factor therapyAntonio Julià, María López-Lasanta, Francisco Blanco, et al.
Pageof 10

Showing results (51-60 of 94) with videos related to

Sort By:
Pageof 10
Plos One|April 8, 2015
Variation at FCGR2A and functionally related genes is associated with the response to anti-TNF therapy in rheumatoid arthritisGabriela Avila-Pedretti, Jesús Tornero, Antonio Fernández-Nebro, et al.
International Journal of Molecular Sciences|September 27, 2025
Differential Expression of Galectin-1 and Galectin-9 in Immune-Mediated Inflammatory DiseasesCristina Valero-Martínez, Marisa Pardines-Ortiz, Nuria Montes, et al.
Frontiers in Immunology|July 18, 2019
A Combined Transcriptomic and Genomic Analysis Identifies a Gene Signature Associated With the Response to Anti-TNF Therapy in Rheumatoid ArthritisAdrià Aterido, Juan D Cañete, Jesús Tornero, et al.
Medicine|June 29, 2017
Cardiovascular disease in immune-mediated inflammatory diseases: A cross-sectional analysis of 6 cohortsBenjamín Fernández-Gutiérrez, Pedro P Perrotti, Javier P Gisbert, et al.
Annals of the Rheumatic Diseases|June 27, 2009
Loss of imprinting of IGF2 characterises high IGF2 mRNA-expressing type of fibroblast-like synoviocytes in rheumatoid arthritisAlejandro Martin-Trujillo, Johanna G I van Rietschoten, Trieneke C G Timmer, et al.
Pharmacogenomics|May 9, 2013
GWAS replication study confirms the association of PDE3A-SLCO1C1 with anti-TNF therapy response in rheumatoid arthritisIsabel Acosta-Colman, Núria Palau, Jesús Tornero, et al.
BMC Medicine|September 10, 2016
Urine metabolome profiling of immune-mediated inflammatory diseasesArnald Alonso, Antonio Julià, Maria Vinaixa, et al.
Reumatologia Clinica|June 9, 2015
2014 update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological therapies in rheumatoid arthritisRaimon Sanmartí, Susana García-Rodríguez, José María Álvaro-Gracia, et al.
Seminars in Arthritis and Rheumatism|May 20, 2020
Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugsXabier Michelena, Helena Borrell, Mireia López-Corbeto, et al.
BMC Musculoskeletal Disorders|April 22, 2021
Interactions between rheumatoid arthritis antibodies are associated with the response to anti-tumor necrosis factor therapyAntonio Julià, María López-Lasanta, Francisco Blanco, et al.
Pageof 10